Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04792281 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis

Study acronym: PET-NAVIE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 22, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revised at 1 of 6 sitesv5
  2. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v4
  3. Start date changed from estimate of Mar 30, 2021 to Aug 31, 2021v3
  4. Trial status: Not Yet Recruiting to Recruitingv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General Hospital , the McGill University Health Centre and the CHUS.
Trial Details
NCT Number NCT04792281
Lead Sponsor Montreal Heart Institute
Conditions
(from sponsor)		 Infective Endocarditis, Native Valve Endocarditis
Related terms Endocarditis
Enrollment 97 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov